From Organigram Cuts to Question 8 Funding
In today’s Trade To Black podcast presented by Flowhub, Shadd Dales and Anthony Varrell welcome Organigram Global CEO James Yamanaka to break down the company’s latest restructuring. Dr. Paul Shields of Vantage Hemp returns for the weekly Vantage Standard segment, and FundCanna CEO Adam Stettner follows the money behind Massachusetts Question 8.
Organigram has completed its integration of Sanity Group and moved to a unified global operating model. The company expects $8 million to $10 million in annualized savings, with $5 million to $6 million landing in fiscal 2027 and about $2 million in one-time costs. Yamanaka says the company is also discontinuing three brands to concentrate on SHRED, BOXHOT and Big Bag O’ Buds. In Germany, demand still outpaces supply, and the Berlin authority is now reviewing the Moncton facility’s EU-GMP application.
Yamanaka declined to comment on rumors involving Aurora. He did say M&A activity is heating up and that scale will be key to attracting institutional investors. He also expects consolidation in Canada’s adult-use market, though he’s unsure how quickly it will come.
Dr. Shields addresses opponents’ challenges to the HHS review. He argues that differences between the older and newer reports reflect new authors and a larger body of literature, not bias, since both used the same methodology. He separates physical dependence from abuse and says opioids carry far greater abuse potential than cannabis. He welcomes the scrutiny, saying the evidence will hold up.
Stettner reports that the Coalition for a Healthy Massachusetts has raised about $3.5 million, with roughly 98.5% coming from SAM Action Inc., a Virginia nonprofit. Out of 5.1 million registered voters in the state, he found just six Massachusetts residents had donated, for a total of $1,600. He notes that the state’s adult-use market has generated about $2 billion in taxes, much of it reinvested in prevention, treatment and public safety. A recent MassINC poll found 61% of likely voters opposed to repeal and 27% in favor.
Stettner says a repeal wouldn’t take effect until January 2028, so FundCanna is still lending in Massachusetts. If the measure passed, though, the company would likely wind down its adult-use programs there. In his view, prohibition simply hands the market back to illicit sellers.
Get the full picture when you tune in.
